Nankervis Craig A, Preston Thomas J, Dysart Kevin C, Wilkinson Whitney D, Chicoine Louis G, Welty Stephen E, Nelin Leif D
Neonatal ECMO Program, Columbus Children's Hospital, Columbus, Ohio, USA.
ASAIO J. 2007 Jan-Feb;53(1):111-4. doi: 10.1097/01.mat.0000247777.65764.b3.
We studied 12 consecutive neonates placed on venoarterial extracorporeal membrane oxygenation (ECMO) in 2004-2005. Activated clotting times (ACT) and anti-factor Xa levels were measured, and the corresponding heparin drip rate was noted. The mean heparin drip rate was 42.2 +/- 10.9 (SD) U/kg/hour (range 20.0-69.5 U/kg/hour). There were 55 simultaneous ACT and anti-factor Xa samples drawn. The mean ACT was 167 +/- 20 seconds (range 128-227 seconds). There was no correlation between ACT levels and heparin dose (r = 0.21; p = 0.12). The mean anti-factor Xa activities were 0.73 +/- 0.19 U/ml (range 0.1-1.0 U/ml). There was a correlation (r = 0.75; p < 0.0001) between anti-factor Xa and heparin dose. We also examined the effect of day on ECMO on heparin drip rate, ACT, and anti-factor Xa. There was no correlation between day on ECMO and either heparin drip rate (r = 0.21, p = 0.12) or ACT (r = 0.002, p = 0.99). However, there was a positive correlation (r = 0.46, p < 0.0005) between day on ECMO and anti-factor Xa activities. In these neonatal patients on venoarterial ECMO, ACT was not a reliable indicator of heparin effect. Furthermore, the increase in anti-factor Xa levels with time on ECMO suggests that heparin accumulates and/or that anti-thrombin III levels decrease with time on ECMO.
我们研究了2004年至2005年期间连续接受静脉-动脉体外膜肺氧合(ECMO)治疗的12例新生儿。测量活化凝血时间(ACT)和抗Xa因子水平,并记录相应的肝素滴注速率。肝素平均滴注速率为42.2±10.9(标准差)U/kg/小时(范围为20.0 - 69.5 U/kg/小时)。共采集了55份ACT和抗Xa因子的同步样本。ACT平均为167±20秒(范围为128 - 227秒)。ACT水平与肝素剂量之间无相关性(r = 0.21;p = 0.12)。抗Xa因子平均活性为0.73±0.19 U/ml(范围为0.1 - 1.0 U/ml)。抗Xa因子与肝素剂量之间存在相关性(r = 0.75;p < 0.0001)。我们还研究了ECMO治疗天数对肝素滴注速率、ACT和抗Xa因子的影响。ECMO治疗天数与肝素滴注速率(r = 0.21,p = 0.12)或ACT(r = 0.002,p = 0.99)均无相关性。然而,ECMO治疗天数与抗Xa因子活性之间存在正相关性(r = 0.46,p < 0.0005)。在这些接受静脉-动脉ECMO治疗的新生儿患者中,ACT并非肝素效果的可靠指标。此外,随着ECMO治疗时间的延长,抗Xa因子水平升高表明肝素会蓄积和/或抗凝血酶III水平会随着ECMO治疗时间的延长而降低。